Treatment of Drug Dependence and Psychiatric Illness

药物依赖和精神疾病的治疗

• 批准号: 6430161
• 负责人: Roger D. Weiss
• 金额: $ 11.81万
• 依托单位: MCLEAN HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-20 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6430161
• 关键词: behavioral /social science research tag; bipolar depression; clinical chemistry; clinical research; cocaine; cognitive behavior therapy; combination therapy; comorbidity; drug abuse prevention; drug addiction; group counseling; group therapy; human subject; human therapy evaluation; interview; mental disorder chemotherapy; outcomes research; patient oriented research; relapse /recurrence; therapy compliance

DESCRIPTION: (provided by the applicant) The primary aim of this K02 competing renewal application is to further the applicant?s scientific development in the area of treatment of drug dependent patients, particularly those who are "dually diagnosed" with drug abuse and coexisting psychiatric illness. Two major hypotheses guide the applicant?s current and planned research. The first is that since drug dependent and dually diagnosed patients are a heterogeneous group, identifying meaningful subgroups of patients and targeting specific therapies to these subgroups will improve treatment outcome. The second major hypothesis is that studying the integration of different treatment approaches (e.g., the combination of pharmacotherapy and psychotherapy) can lead to improved treatment for drug dependent patients. This application is designed to strengthen the applicant?s involvement in five funded projects as PI or Co-Investigator. The following funded projects are currently being pursued by the applicant: 1) a NIDA Behavioral Therapies Development Project to compare two different forms of group therapy for patients with bipolar disorder and substance dependence (DA09400, PI); 2) a multi-site randomized controlled trial evaluating combinations of pharmacotherapy and behavioral therapies in the treatment of alcohol dependence (AA11756, Site PI); 3) a multi-site study examining the genetics of cocaine dependence (DA12849, Site PI); 4) a NIDA-funded project examining the potential efficacy of CDP-choline in the treatment of cocaine dependence (DA11098, Co-Investigator); and 5) a multicenter NIMH-funded project to examine optimal treatments for individuals with bipolar disorder, for which the applicant will examine treatments for those patients with coexisting substance use disorder (MH80001, Substance Abuse Pathway Leader and Co-Investigator). The applicant proposes to expand his research capabilities by learning more about genetics and statistical methods through guided tutorials. Finally, the applicant will mentor younger investigators in their drug abuse research careers and serve the field in general through work as a reviewer on the NIDA Treatment Research IRG and participation in national organizations and editorial boards of addiction journals.

描述：（由申请人提供） 此 K02 竞争性续展申请的主要目的是进一步促进 申请人在药物依赖治疗领域的科学进展 患者，特别是那些被“双重诊断”患有药物滥用和 并存的精神疾病。两个主要假设指导申请人 当前和计划中的研究。首先是由于药物依赖性和双重性 确诊患者是一个异质群体，确定有意义的亚组 患者的数量和针对这些亚组的针对性治疗将得到改善 治疗结果。第二个主要假设是研究整合 不同的治疗方法（例如药物治疗和药物治疗相结合） 心理治疗）可以改善药物依赖患者的治疗。这 申请旨在加强申请人对五个方面的参与 作为 PI 或 Co-Investigator 资助的项目。以下资助项目是 申请人目前正在寻求： 1) NIDA 行为疗法 比较两种不同形式的团体治疗的开发项目 双相情感障碍和物质依赖患者（DA09400，PI）； 2）一个 评估组合的多中心随机对照试验 治疗酒精依赖的药物疗法和行为疗法 （AA11756，网站 PI）； 3) 一项检查可卡因遗传学的多中心研究 依赖性（DA12849，站点 PI）； 4) NIDA 资助的项目，检查潜力 CDP-胆碱治疗可卡因依赖的功效（DA11098， 联合研究员）； 5) 一个由 NIMH 资助的多中心项目，用于检验最佳 针对双相情感障碍患者的治疗，申请人将 检查对同时存在物质使用障碍的患者的治疗方法 （MH80001，药物滥用途径领导者和联合研究员）。申请人 提议通过更多地了解遗传学来扩展他的研究能力 以及通过指导教程进行的统计方法。最后，申请人将 指导年轻研究人员的药物滥用研究生涯并为 通过担任 NIDA 治疗研究 IRG 的审稿人，了解整个领域的情况 并参与国家组织和成瘾编辑委员会 期刊。